<DOC>
	<DOC>NCT01220570</DOC>
	<brief_summary>This clinical trial will evaluate whether treatment with ridaforolimus, dalotuzumab, or ridforolimus/dalotuzumab combination therapy reduces Growth Factor Signature (GFS) Score among participants with breast cancer.</brief_summary>
	<brief_title>The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Participant has operable Stage IIIIa invasive breast cancer of the following subtype: ERpositive, HER2negative tumor with histologic grade 2 or 3 and Ki67 â‰¥ 15% Tumor is at least 2 cm in diameter as assessed by physical or radiographic exam Participant consents to provide an existing tissue sample or to have a core needle biopsy before drug administration Participant consents to provide tissue samples following drug administration by a second core needle biopsy or from a surgical specimen Participant must have adequate organ function Participant has received any prior chemotherapy, biological therapy or radiotherapy for breast cancer Participant has a known hypersensitivity to the components of study drugs or their analogs, including hypersensitivity to macrolide antibiotics (e.g. clarithromycin, erythromycin, azithromycin). Participant has poorly controlled diabetes mellitus, or requires insulin for glucose control. Participant is unable to swallow capsules and/or absorb oral medications Participant is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study. Participant is known to be Human Immunodeficiency Virus (HIV)positive Participant has known history of active Hepatitis B or C. Participant is concurrently using growth hormone (GH) or growth hormone inhibitors Participant has significant or uncontrolled cardiovascular disease, including heart failure, unstable angina, or a myocardial infarction within the last 6 months</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>ridaforolimus</keyword>
	<keyword>ridaforolimus/dalotuzumab combination therapy</keyword>
</DOC>